Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should young patients with neuroblastoma receive high-dose platinum compounds?

Nature Clinical Practice Oncology volume 4, pages 16–17 (2007)Cite this article

boxed-textKushner BH et al. (2006) Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107: 417–422

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Brock P et al. (1988) Ototoxicity of high-dose cisplatinum in children. Med Pediatr Oncol 16: 368–369

    Article  CAS  Google Scholar 

  2. Brock PR et al. (1991) Cisplatin ototoxicity in children; a practical grading system. Med Pediatr Oncol 19: 295–300

    Article  CAS  Google Scholar 

  3. Freilich RJ et al. (1996) Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue. Med Pediatr Oncol 26: 95–100

    Article  CAS  Google Scholar 

  4. Pfeifle CE et al. (1985) High dose cisplatin with sodium thiosulphate protection. J Clin Oncol 3: 237–244

    Article  CAS  Google Scholar 

  5. Neuwelt EA et al. (1998) First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulphate. J Pharmacol Exp Ther 286: 77–84

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Great Ormond Street Hospital for Children NHS Trust, Great Ormond Street, London WC1N 3JH, UK brockp@gosh.nhs.uk

Authors and Affiliations

  1. PR Brock is currently Consultant Paediatric Oncologist at Great Ormond Street Hospital and Honorary Senior Lecturer at the Institute of Child Health, London, UK.,

    Penelope R Brock

Authors
  1. Penelope R Brock
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brock, P. Should young patients with neuroblastoma receive high-dose platinum compounds?. Nat Rev Clin Oncol 4, 16–17 (2007). https://doi.org/10.1038/ncponc0683

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0683

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing